Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...

Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

Based on the results of a non-inferiority study, in January 2018 the U.S. Food and Drug Administration (FDA) approved the use of denosumab for the prevention of skeletal events in patients with ...

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method Bone ...

The Food and Drug Administration (FDA) has approved Osvyrti ® (denosumab-desu), a biosimilar to Prolia ® (denosumab), and Jubereq ® (denosumab-desu), a biosimilar to Xgeva ® (denosumab). Osvyrti is ...

The US Food and Drug Administration (FDA) has approved denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture, defined as defined ...

The Food and Drug Administration (FDA) has approved the use of Prolia (denosumab; Amgen) for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture who are ...

Denosumab (Prolia, Amgen, Inc) does not appear to delay fracture healing or cause other complications when given at or near the time of fracture in postmenopausal women with osteoporosis, according to ...

THOUSAND OAKS, Calif., Oct. 19 Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...